This phase III trial is comparing the safety and effectiveness of two targeted cancer therapies, given in combination with a standard cancer treatment, for patients with multiple myeloma that has gotten worse or come back following prior treatment.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Eligible patients will be randomised 1:1 into Arm A or Arm B of the study. Patients enrolled in Arm A will receive Belantamab mafodotin in combination with Bortezomib plus Dexamethasone. Patients enrolled in Arm B will Daratumumab in combination with Bortezomib plus Dexamethasone.
Recruiting Hospitals Read More